SLC9A1 and Stroke: Taken together, these data clearly demonstrate that the delayed administration of Rimeporide to block NHE1 protein activity from 24 h post-stroke stimulated OL genesis and differentiation, while reducing OL apoptosis, leading to improved white matter myelination in post-stroke brains, similar to the HOE-mediated effects.